PharmaFocus Today – Page 86 – media

Exercising just one or two days a week can also lead to long-term health benefits.

The latest research by Chinese scientists shows that people can achieve the health benefits of daily exercise by engaging in physical activities for moderate to vigorous intensity for 1 to 2 days a week, as long as the total duration is at least 150 minutes per week. This research report was published in the recent issue of the “American Heart Association Journal”. Dr. Li Zhihao, an epidemiologist from Southern Medical University in Guangzhou, said that engaging in 150 minutes of moderate to vigorous physical activity per week, whether concentrated in 1 to 2 days or spread out over time, can significantly reduce the risk of death from cardiovascular diseases, cancer, or other causes. Those who cannot schedule physical exercise every day can focus on high-intensity activities on weekends. This study provides reliable evidence that even occasional physical activity can bring long-term health benefits, making it easier for people to prioritize ...
- Source: drugdu
- 112
- May 8, 2025
The Neuralink brain computer interface device has obtained FDA’s “Breakthrough Device” certification; Hengrui Pharmaceutical Passes Hong Kong Stock Exchange Listing Hearing | Pharmaceutical Early Participation

NO.1 Hengrui Pharmaceutical has passed the listing hearing on the Hong Kong Stock Exchange and may be listed as early as May On May 5th, the Hong Kong Stock Exchange website posted the PHIP version of Hengrui Pharmaceutical’s prospectus, which the market interpreted as indicating that Hengrui Pharmaceutical has officially passed the hearing of the Hong Kong Stock Exchange. Hengrui Pharmaceutical told the Daily Economic News reporter that this move marks a crucial progress for the company’s listing in Hong Kong. According to informed sources, Hengrui Pharmaceutical may be officially listed and traded on the Hong Kong Stock Exchange as early as May. Commentary: If Hengrui Pharmaceutical successfully goes public on the Hong Kong stock market this time, it will be its first equity financing after its A-share IPO and a key milestone in its internationalization strategy. From the current development trend of the pharmaceutical industry, overseas markets have ...
- Source: drugdu
- 181
- May 7, 2025
21 Health News Daily | The actual controller and chairman of Yong’an Pharmaceutical have been detained; Ha Sanlian and related personnel received a warning letter from Heilongjiang Securities Regulatory Bureau

Large expansion of grassroots drug catalog On April 30th, the National Health Commission issued the “Guiding Opinions on Optimizing the Layout and Construction of Grassroots Medical and Health Institutions”, once again clarifying the need to expand the types of drugs used for common and chronic diseases at the grassroots level, and promote the unification of drug catalogs for county-level medical communities. The Opinion guides various regions to comprehensively coordinate the development of urban-rural integration, changes in population structure, and public health needs, and to improve the layout and construction of grassroots medical and health institutions according to local conditions. This is in line with the State Council executive meeting’s proposal to “improve the construction layout according to local conditions”. The core goal of the policy is to optimize resource allocation and improve service capabilities, promote the implementation of tiered diagnosis and treatment, and achieve a medical pattern of “minor ...
- Source: drugdu
- 136
- May 7, 2025
The Neuralink brain computer interface device has obtained FDA’s “Breakthrough Device” certification; Hengrui Pharmaceutical Passes Hong Kong Stock Exchange Listing Hearing | Pharmaceutical Early Participation

NO.1 Hengrui Pharmaceutical has passed the listing hearing on the Hong Kong Stock Exchange and may be listed as early as May On May 5th, the Hong Kong Stock Exchange website posted the PHIP version of Hengrui Pharmaceutical’s prospectus, which the market interpreted as indicating that Hengrui Pharmaceutical has officially passed the hearing of the Hong Kong Stock Exchange. Hengrui Pharmaceutical told the Daily Economic News reporter that this move marks a crucial progress for the company’s listing in Hong Kong. According to informed sources, Hengrui Pharmaceutical may be officially listed and traded on the Hong Kong Stock Exchange as early as May. Commentary: If Hengrui Pharmaceutical successfully goes public on the Hong Kong stock market this time, it will be its first equity financing after its A-share IPO and a key milestone in its internationalization strategy. From the current development trend of the pharmaceutical industry, overseas markets have ...
- Source: drugdu
- 180
- May 7, 2025
21 Health News Daily | The actual controller and chairman of Yong’an Pharmaceutical have been detained; Ha Sanlian and related personnel received a warning letter from Heilongjiang Securities Regulatory Bureau

On April 30th, the National Health Commission issued the “Guiding Opinions on Optimizing the Layout and Construction of Grassroots Medical and Health Institutions”, once again clarifying the need to expand the types of drugs used for common and chronic diseases at the grassroots level, and promote the unification of drug catalogs for county-level medical communities. The Opinion guides various regions to comprehensively coordinate the development of urban-rural integration, changes in population structure, and public health needs, and to improve the layout and construction of grassroots medical and health institutions according to local conditions. This is in line with the State Council executive meeting’s proposal to “improve the construction layout according to local conditions”. The core goal of the policy is to optimize resource allocation and improve service capabilities, promote the implementation of tiered diagnosis and treatment, and achieve a medical pattern of “minor illnesses not leaving the village and ...
- Source: drugdu
- 190
- May 7, 2025
The “insulin leader” saw a 1150% surge in net profit

On April 25, Ganli Pharmaceutical, a leading insulin company, released its first quarter report for 2025, reporting an excellent performance with both revenue and net profit growing. According to the report, the company’s Q1 operating income reached 985 million yuan, a year-on-year increase of 75.76%; net profit attributable to shareholders of listed companies reached 312 million yuan, a year-on-year increase of 224.9%; net profit attributable to shareholders after deducting non-recurring items reached 215 million yuan, a year-on-year increase of 1150.2%. From the perspective of revenue structure, Gan & Lee Pharmaceuticals achieved significant growth in both domestic and overseas revenue, which jointly drove the increase in overall revenue. In the domestic market, Ganli Pharmaceuticals performed strongly, with sales revenue reaching 889 million yuan, an increase of 395 million yuan over the same period last year, a year-on-year increase of 80.07%. This is mainly due to the substantial increase in sales of ...
- Source: drugdu
- 201
- May 5, 2025
Yahong Pharmaceutical’s loss in the first quarter widened to 83.53 million yuan

On April 29, Yahong Pharmaceutical (688176) announced its first quarter report for 2025. The company’s operating income was 61.10 million yuan, up 151.2% year-on-year; the net profit attributable to the parent company changed from a loss of 82.85 million yuan in the same period last year to a loss of 83.53 million yuan, and the loss amount further expanded; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 93.23 million yuan in the same period last year to a loss of 89.35 million yuan, and the loss amount decreased; the net operating cash flow was -110 million yuan, up 14.5% year-on-year; EPS (fully diluted) was -0.1465 yuan. As of the end of the first quarter, the company’s total assets were 2.162 billion yuan, down 2.8% from the end of the previous year; the net assets attributable to the parent company were 1.891 ...
- Source: drugdu
- 308
- May 5, 2025
the core of stem cell therapy is safety, effectiveness and quality control

Shanghai Securities News (reporter Liu Yipeng) “At the beginning of this year, the first stem cell drug in China was approved for listing, marking a new stage of standardization and standardization of the industry. At present, many stem cell varieties have entered phase II and phase III clinical trials. Hainan Boao Music City International Medical Tourism Pioneer Zone has passed the policy of” first trial first “, providing an important test ground for clinical transformation.” On April 25, at the 2025 Boao Stem Cell Industry Conference, Wang Guangji, an academician of the CAE Member and professor of China Pharmaceutical University, said in an exclusive interview with reporters from Shanghai Securities News that the core of stem cell therapy is safe, effective and quality controllable, and only through strict standards. Only the stem cell products produced in chemical production, reviewed by the drug supervision department and clinically verified can truly benefit ...
- Source: drugdu
- 213
- May 4, 2025
The incidence of vaccine-preventable diseases is rising

According to the official website of the World Health Organization (WHO) on April 24, during the “World Immunization Week” held from the 24th to the 30th, WHO, UNICEF and the Global Vaccine Immunity Alliance jointly issued a warning that due to the spread of misinformation and the reduction of international aid, diseases that could have been prevented by vaccines, such as measles, meningitis and yellow fever, are on the rise worldwide. The three major international organizations urgently called on countries to continue to invest political attention and funds to consolidate the results of immunization programs and safeguard the significant progress made in reducing child mortality in the world over the past half century. The latest monitoring data show that measles cases have increased year by year since 2021. In 2023, there were 10.3 million cases, an increase of 20% from 2022. In the past 12 months, 138 countries have reported ...
- Source: drugdu
- 287
- May 4, 2025
Innovative vaccines are accelerating their approval and listing, and the Bio-Vaccine ETF (562860) is expected to benefit

As of 10:42 on April 24, 2025, the CSI Vaccine and Biotechnology Index rose by 0.36%, and its constituent stocks Rongchang Bio rose by 4.38%, Maiwei Bio rose by 4.27%, Qianhong Pharmaceutical rose by 3.47%, Hitech Bio rose by 2.89%, and North China Pharmaceutical rose by 2.33%. The Bio-Vaccine ETF (562860) is in a stalemate between long and short positions. The Bio-Vaccine ETF closely tracks the CSI Vaccine and Biotechnology Index. The CSI Vaccine and Biotechnology Index selects no more than 50 listed companies whose businesses involve vaccine research and development, vaccine production, vaccine consumables, vaccine production equipment and other biotechnology fields as samples to reflect the overall performance of listed companies with vaccine and biotechnology themes. Data shows that as of March 31, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index are Zhifei Bio, Wantai Bio, Watson Bio, Hualan Bio, Kangtai Bio, BeiGene, Junshi ...
- Source: drugdu
- 167
- May 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.